Abbott said that its Afinion HbA1c assay used to diagnose diabetes could eventually be made available in physicians' offices through a CLIA waiver.
Evercore noted that while Qiagen is on target to hit previously issued 2020 financial targets, its recently issued long-term guidance for 2023 is less of a sure thing.
Mirnax will use Arcis' nucleic acid sample preparation and preservation technology to improve the stability of miRNA biomarkers for early disease detection.
The test measures levels of seven autoantibodies to tumor-associated antigens and is designed to detect all forms of lung cancer at any stage.
Nestlé Health said that employees of Prometheus are becoming employees of Precision IBD, with the exception of those working in its point-of-care diagnostic business.
The lack of a ready infrastructure has some manufacturers spooked about a regulatory bottleneck as the date for compliance draws closer.
The UK company plans to launch a CE-IVD version of the test in 2021 and anticipates launch of an FDA-cleared test shortly thereafter.
The German firm, spun off from a marine research institute, recently closed a €1 million seed financing round to support expansion of the company and drive adoption.
The company had a profit of £3.4 million, or £0.01 per share, for the year compared to a loss of £9.6 million, or £0.03 per share, the previous year.
Last month, the Cyprus-based genetic diagnostics company launched a number of hereditary cancer and somatic tumor sequencing panels, its first tests for oncology.